Verco S.A. (Poland)

Verco S.A. is a Polish pharmaceutical company focused on selected therapeutic areas and a portfolio built in close cooperation with medical doctors and scientific circles. Core business segments cover gynecology and womens health, ophthalmology and eye protection, and products supporting surgery-related care such as wound and scar management; the company frames its portfolio approach around Evidence Based Medicine and scientifically supported solutions. In gynecology and womens health, key lines include pregnancy and child care preparations (e.g., Pregna Vomi, Pregna DHA, Pregna Plus, Pregna Start) and intimate-comfort products (e.g., Trivagin bacteria, Ovarin, Trivagin gel, and Mucovagin formats including gel, physiological emulsion and globules). In ophthalmology, the portfolio includes eye-protection and care products such as Dexoftyal (MD/UD), Demoxoft (Clean/Solution/Plus Lipogel), HexaClean, Maculoft, Retixoft Angio and Vitroft. In wound and scar care, the offer includes Sutricon scar products and Sutricon gel. Geographic scope is Poland with distribution supported by dedicated logistics/warehouse operations. Key assets include the branded product portfolio across core therapeutic segments and the organizational capabilities to develop, market and distribute specialized healthcare products in collaboration with clinicians. Strategically, Verco positions around specialized focus areas, clinician-linked product development and education, and a quality and ethics-driven approach to patient-oriented solutions.